SES (SES) Q1 2026 Earnings Call Transcript

SES AI reported Q1 revenue of $6.7 million, up 47% sequentially from $4.6 million, while gross margin improved to 18.1% from 11.3% and adjusted EBITDA loss narrowed to $12.8 million. Management reaffirmed full-year 2026 revenue guidance of $30 million to $35 million and highlighted a $20 million three-year North American distribution deal, early drone cell shipments, and a growing Molecular Universe subscription pipeline. The company ended the quarter with $178 million in cash and reiterated a 15% operating expense reduction plan, but results remain pre-profit and execution-dependent.

Analysis

SES is transitioning from a single-product story to a three-engine commercialization story, but the market will likely underwrite the wrong engine as the primary value driver. The near-term catalyst is not the drone line itself; it is the combination of higher-margin ESS distribution plus a measurable reduction in operating burn starting in Q3, which should create a cleaner inflection in quarterly cash losses before drones become material. That matters because the stock can rerate on visible operating leverage long before revenue scale is large enough to matter on a full-year basis.

The second-order effect is that the drone business may function less as an absolute revenue driver in 2026 and more as a strategic proof point for NDA-compliant manufacturing capability. If customer qualification really takes 1-2 quarters and most testing is already complete, then Q2/Q3 shipments are the bridge from “pipeline” to “orderbook,” which can trigger a sentiment shift even if initial dollars are modest. The real scarcity value here is supply-chain compliance: defense-oriented buyers may pay for speed, traceability, and domestic/regional auditability, which creates a pricing floor well above generic cell economics.

The least appreciated variable is dilution/financing optionality. With ~$178M of cash and an S-3 refresh coming, management is signaling flexibility rather than distress; that reduces near-term existential risk but also keeps the equity overhang alive if execution slips or the ramp stalls. The market should treat the guidance reaffirmation as credible only if Q2 shows sequential conversion in all three businesses, because the current setup is still heavily dependent on shipments rather than recurring demand.

Contrarian angle: consensus is likely to overreact to the drone TAM and underreact to the AI/software layer. Molecular Universe’s direct revenue may remain small, but its on-premise deployment can create sticky enterprise relationships and pull-through across ESS and materials; the optionality is in cross-sell and data moat, not standalone subscription dollars. If that linkage starts to show up in order flow, the multiple can expand well before the income statement catches up.

Key Decisions for Investors

• Long SES into the next 1-2 earnings/revenue updates: thesis is Q2/Q3 shipment conversion plus Q3 expense step-down. Risk/reward is attractive if the stock is still pricing SES as a pre-revenue hardware story; trim if revenue growth stalls or burn stays flat.
• Use call spreads in SES rather than outright stock for a 3-6 month catalyst window: favors upside from sequencing of drone shipments and operating leverage while capping downside if qualification slips.
• Pair trade: long SES / short a basket of higher-duration speculative clean-tech names with weaker balance sheets. SES has more cash runway and clearer shipment catalysts; this works best over 1-2 quarters if execution remains intact.
• If looking for lower-risk exposure, wait for evidence of Q2 revenue conversion before adding. The setup improves materially if management shows ATGE shipments booked and drone revenue begins to appear, reducing reliance on narrative alone.
• Monitor for dilution risk around the new S-3. If the stock spikes on drone headlines without corresponding cash-flow improvement, consider selling strength or hedging with puts into the filing window.